Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.

M AmbrosiniB RousseauP MancaO ArtzA MarabelleT AndréG MaddalenaG MazzoliR IntiniR CohenA CercekN H SegalL SaltzA M VargheseR YaegerM NusratZ GoldbergG Y KuI El DikaO MargalitA GrinshpunP Murtaza KasiR SchilskyA LutfiE Shacham-ShmueliM Khan AfghanL WeissC B WestphalenV ConcaB DeckerG RandonE ElezM FakihA B SchrockC CremoliniP JayachandranM J OvermanS LonardiF Pietrantonio

Published in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)

Patients with POLE/D1pd mCRC showed more favorable outcomes compared to dMMR/MSI-H mCRC to treatment with ICIs in terms of tumor response and survival.

Keyphrases

metastatic colorectal cancer
type diabetes
adipose tissue
insulin resistance
weight loss